XTL Biopharmaceuticals Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XTLB.TA research report →
Price Chart
About the company
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, addressing systemic lupus erythematosus and Sjogren's syndrome.
- CEO
- Noam Band
- IPO
- 2005
- Employees
- 10
- HQ
- Herzliya, TA, IL
Get TickerSpark's AI analysis on XTLB.TA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.92M
- P/E
- -0.84
- PEG
- 0.01
- P/S
- 0.00
- P/B
- -23.62
- EV/EBITDA
- -5.16
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -269.02%
- ROIC
- -11253.33%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-1,688,000
- Net Income
- $-6,969,000-578.6%
- EPS
- $-0.01-433.3%
- OCF Growth
- +36.7%
- FCF Growth
- +38.7%
- 52W High
- $2.20
- 52W Low
- $0.02
- 50D MA
- $1.95
- 200D MA
- $0.66
- Beta
- 0.55
- RSI (14)
- 49
- Avg Volume
- 2.84M
No earnings-call transcripts are available for XTLB.TA yet.
- Free Float
- 67.9%
- Shares Outstanding
- 946.24M
- Float Shares
- 642.09M
Our XTLB.TA coverage
Recent articles, reports, and earnings notes.
No research on XTLB.TA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XTLB.TA report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.